Loredana Santo1, Brian W Ward2, Pinyao Rui2, Jill J Ashman2. 1. Division of Health Care Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Rd. Rm. 3534, Hyattsville, MD, 20782, USA. nta3@cdc.gov. 2. Division of Health Care Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Rd. Rm. 3534, Hyattsville, MD, 20782, USA.
Abstract
PURPOSE: Cancer treatment may be affected by comorbidities; however, studies are limited. The purpose of this study is to examine the frequency of comorbidities at visits by patients with breast, prostate, colorectal, and lung cancer and to estimate frequency of a prescription for antineoplastic drugs being included in the treatment received at visits by patients with cancer and concomitant comorbidities. METHODS: We used nationally representative data on visits to office-based physicians from the 2010-2016 National Ambulatory Medical Care Survey and selected visits by adults with breast, prostate, colorectal, or lung cancer (n = 4,672). Nineteen comorbid conditions were examined. Descriptive statistics were calculated for visits by cancer patients with 0, 1, and ≥ 2 comorbidities. RESULTS: From 2010-2016, a total of 10.2 million physician office visits were made annually by adult patients with breast, prostate, colorectal, or lung cancer. Among US visits by adult patients with breast, prostate, colorectal, or lung cancer, 56.3% were by patients with ≥ 1 comorbidity. Hypertension was the most frequently observed comorbidity (37.7%), followed by hyperlipidemia (19.0%) and diabetes (12.3%). Antineoplastic drugs were prescribed in 33.5% of the visits and prescribed at a lower percentage among visits by cancer patients with COPD (21.3% versus 34.3% of visits by cancer patients without COPD) and heart disease (22.7% versus 34.2% of visits by cancer patients without heart disease). CONCLUSION: Our study provides information about comorbidities in cancer patients being treated by office-based physicians in an ambulatory setting.
PURPOSE:Cancer treatment may be affected by comorbidities; however, studies are limited. The purpose of this study is to examine the frequency of comorbidities at visits by patients with breast, prostate, colorectal, and lung cancer and to estimate frequency of a prescription for antineoplastic drugs being included in the treatment received at visits by patients with cancer and concomitant comorbidities. METHODS: We used nationally representative data on visits to office-based physicians from the 2010-2016 National Ambulatory Medical Care Survey and selected visits by adults with breast, prostate, colorectal, or lung cancer (n = 4,672). Nineteen comorbid conditions were examined. Descriptive statistics were calculated for visits by cancerpatients with 0, 1, and ≥ 2 comorbidities. RESULTS: From 2010-2016, a total of 10.2 million physician office visits were made annually by adult patients with breast, prostate, colorectal, or lung cancer. Among US visits by adult patients with breast, prostate, colorectal, or lung cancer, 56.3% were by patients with ≥ 1 comorbidity. Hypertension was the most frequently observed comorbidity (37.7%), followed by hyperlipidemia (19.0%) and diabetes (12.3%). Antineoplastic drugs were prescribed in 33.5% of the visits and prescribed at a lower percentage among visits by cancerpatients with COPD (21.3% versus 34.3% of visits by cancerpatients without COPD) and heart disease (22.7% versus 34.2% of visits by cancerpatients without heart disease). CONCLUSION: Our study provides information about comorbidities in cancerpatients being treated by office-based physicians in an ambulatory setting.
Entities:
Keywords:
Ambulatory health care; Antineoplastic drugs prescription; Cancer visits; Comorbidities
Authors: Sydney M Dy; Phoebe Sharkey; Robert Herbert; Kathleen Haddad; Albert W Wu Journal: Crit Rev Oncol Hematol Date: 2006-07-07 Impact factor: 6.312
Authors: Claire F Snyder; Kevin D Frick; Robert J Herbert; Amanda L Blackford; Bridget A Neville; Klaus W Lemke; Michael A Carducci; Antonio C Wolff; Craig C Earle Journal: J Cancer Surviv Date: 2015-02-26 Impact factor: 4.442
Authors: Lonneke V van de Poll-Franse; Saskia Houterman; Maryska L G Janssen-Heijnen; Marcus W Dercksen; Jan Willem W Coebergh; Harm R Haak Journal: Int J Cancer Date: 2007-05-01 Impact factor: 7.396
Authors: Reina Haque; Jiaxiao Shi; Joanne E Schottinger; Syed A Ahmed; T Craig Cheetham; Joanie Chung; Chantal Avila; Ken Kleinman; Laurel A Habel; Suzanne W Fletcher; Marilyn L Kwan Journal: J Natl Cancer Inst Date: 2015-12-01 Impact factor: 13.506
Authors: Diana Sarfati; Sarah Hill; Tony Blakely; Bridget Robson; Gordon Purdie; Elizabeth Dennett; Donna Cormack; Kevin Dew Journal: BMC Cancer Date: 2009-04-20 Impact factor: 4.430
Authors: M L Gregorowitsch; A Ghedri; D A Young-Afat; R Bijlsma; I O Baas; C van Schaik-van de Mheen; M J Agterof; E Göker; D Ten Bokkel Huinink; H J G D van den Bongard; H M Verkooijen Journal: Breast Cancer Res Treat Date: 2019-02-12 Impact factor: 4.872